Leerink Partners analyst Mani Foroohar has maintained their bullish stance on NTLA stock, giving a Buy rating on February 28.
Mani Foroohar’s rating is based on a combination of factors that include the recent financial disclosures from Intellia Therapeutics. The company’s fourth-quarter earnings report prompted an update to the financial model, resulting in an increased price target from $39 to $40.
These adjustments reflect a positive outlook on Intellia’s financial performance and potential growth, which supports the Buy rating. The decision is further backed by the company’s alignment with the S&P 600 Health Care Index, indicating a strong position within the sector.
In another report released on February 28, JonesTrading also reiterated a Buy rating on the stock with a $33.00 price target.
Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of NTLA in relation to earlier this year.